People taking abacavir (found in Ziagen, Epzicom and Trizivir) had no greater risk of having a heart attack than people not taking abacavir, according to an analysis of six AIDS Clinical Trials Group (ACTG) studies reported in the April 1 issue of Clinical Infectious Diseases. Though the studies predominantly involved people with low cardiovascular disease (CVD) risks, the ACTG analysis joins other reports in challenging the conclusions of studies suggesting that abacavir treatment increases the risk of CVD among people living with HIV.